Cardiovascular Safety and State-of-the-art Development Issues 2012: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity

Posted:
19
March 2012

Join Richmond Pharmacology next month for the DIA Cardiovascular Safety and State-of-the-art Development Issues meeting taking place 17 to 18 April 2012 in Washington.The meeting will address present issues surrounding Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity during a series of debate-style presentations from international industry, academic, and regulatory speakers.Dr Jorg Taubel's current research is concerned with the cardiovascular effects of meals, insulin and C-peptide in Caucasian and Japanese populations. He will be presenting some of his most recent findings on Day 2 (18 Apr 2012), covering the following topics of discussion:Session 6, CV Safety Track at 10h30:

  • Moxifloxacin effect on the QTc interval in fed and fasted states in Thorough QT studies

Session 4, Diabetes Track at 11h00:

  • Insulin does not prolong the QT interval in thorough QT studies performed in healthy volunteers

For further information on Richmond Pharmacology�s specialist Cardiovascular Safety expertise or to request a copy of our latest TQT publication, contact a member of our Business Development team today. Alternatively we hope to see you in the US next month!

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more